| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 225,467 | 74,940 | ||
| Short-term investments | 737,068 | 783,195 | ||
| Accounts receivable | 1,808 | 8,410 | ||
| Prepaid expenses and other current assets | 13,006 | 19,997 | ||
| Total current assets | 977,349 | 886,542 | ||
| Long-term investments | 288,817 | 178,201 | ||
| Property and equipment, net | 76,001 | 70,219 | ||
| Operating lease right-of-use assets | 77,580 | 76,120 | ||
| Other assets | 16,810 | 14,553 | ||
| Total assets | 1,436,557 | 1,225,635 | ||
| Accounts payable | 22,084 | 16,228 | ||
| Accrued liabilities | 61,633 | 52,315 | ||
| Short-term operating lease liabilities | 20,647 | 19,585 | ||
| Current portion of long-term debt | 17,280 | 14,400 | ||
| Derivative liabilities measured at fair value | 16,900 | 17,600 | ||
| Deferred revenue | 1,612 | 1,344 | ||
| Other current liabilities | 1,988 | 9,592 | ||
| Total current liabilities | 142,144 | 131,064 | ||
| Term loans, net | 158,747 | 159,058 | ||
| Convertible notes, principal amount | 911,662 | - | ||
| Less unamortized debt issuance costs on the convertible notes | 22,138 | - | ||
| Convertible notes, net | 889,524 | 553,987 | ||
| Liabilities related to revenue participation right purchase agreements, net | 504,498 | 489,503 | ||
| Long-term operating lease liabilities | 110,655 | 111,028 | ||
| Liabilities related to rpi transactions measured at fair value | 150,500 | 147,700 | ||
| Other non-current liabilities | 1,612 | 2,015 | ||
| Total liabilities | 1,957,680 | 1,594,355 | ||
| Preferred stock | 0 | 0 | ||
| Common stock | 122 | 119 | ||
| Additional paid-in capital | 2,782,409 | 2,628,829 | ||
| Accumulated other comprehensive income | 34 | -158 | ||
| Accumulated deficit | -3,303,688 | -2,997,510 | ||
| Total stockholders' deficit | -521,123 | -368,720 | ||
| Total liabilities and stockholders' deficit | 1,436,557 | 1,225,635 | ||
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)